Consistent with our previous findings in models of high-risk AML with wildtype TP53 [19], TP-0903 treatment also upregulated pChk1 and pH2AX in MV4-11 (WT) cells (Figures S5 and S6). This evidence concerns the gene TP53 and acute myeloid leukemia.